[BIOSTAR PHARMACEUTICALS ACQUIRES SHAANXI WEINAN HUAREN PHARMACEUTICALS, , . XIANYANG, China, October 25, 2011 -- Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases andnditions, today announced that on October 20, 2011]
[SHARE TRANSFER CONTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS CO., LTD. AND SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. INDEX CHAPATER I DEFINITION AND INTERPRETATION 4 ARTICLE 1 DEFINITION 4 CHAPATER II TRANSFERRED SHARES 5 ARTICLE 2 SHARE TRANSFER 5 ARTICLE 3 TRANSFER PRICE 5 ARTICLE 4 CONDITIONS FOR THE PAYMENT OF] [Form Non-competition Agreement Agreement This Non-competition Agreement (this “ Party A: Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd., a company incorporated under PRC law, with its business license registered number [_] and its legal address registered at No. 13, Weihua Road, Weinan City, Shaanxi Province; Party B: [_], a PRC citizen with the ID number [_]. Whereas Equity Interests Article 1] [BIOSTAR PHARMACEUTICALS SIGNS AGREEMENT TO ACQUIRE SHAANXI WEINAN HUAREN PHARMACEUTICALS, LTD . XIANYANG, China, October 11, 2011 -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, today announced that its wholly owned subsidiary, Shaanxi Aoxing Pharmaceutical, Ltd., entered into a]
[SHARE TRANSFER CONTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS CO., LTD. AND SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. INDEX CHAPATER I DEFINITION AND INTERPRETATION 4 ARTICLE 1 DEFINITION 4 CHAPATER II TRANSFERRED SHARES 5 ARTICLE 2 SHARE TRANSFER 5 ARTICLE 3 TRANSFER PRICE 5 ARTICLE 4 CONDITIONS FOR THE PAYMENT OF] [Form Non-competition Agreement Agreement This Non-competition Agreement (this “ Party A: Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd., a company incorporated under PRC law, with its business license registered number [_] and its legal address registered at No. 13, Weihua Road, Weinan City, Shaanxi Province; Party B: [_], a PRC citizen with the ID number [_]. Whereas Equity Interests Article 1] [BIOSTAR PHARMACEUTICALS SIGNS AGREEMENT TO ACQUIRE SHAANXI WEINAN HUAREN PHARMACEUTICALS, LTD . XIANYANG, China, October 11, 2011 -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, today announced that its wholly owned subsidiary, Shaanxi Aoxing Pharmaceutical, Ltd., entered into a]
[SHARE TRANSFERNTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS AND SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS INDEX CHAPATER I DEFINITION AND INTERPRETATION 4 ARTICLE 1 DEFINITION 4 CHAPATER II TRANSFERRED SHARES 5 ARTICLE 2 SHARE TRANSFER 5 ARTICLE 3 TRANSFER PRICE] [Form Non-competitionreementreement This Non-competitionreement (this Party A:Shaanxi Weinan Huaren Pharmaceuticals ampanyorporated under law, with its business license registered number [_] and its legaldress registered at No. 13, Weihua Road, Weinan City, Shaanxi Province; Party B:[_], a citizen with the ID number [_].] [BIOSTAR PHARMACEUTICALS SIGNSREEMENT TO ACQUIRE SHAANXI WEINAN HUAREN PHARMACEUTICALS, . XIANYANG, China, October 11, 2011 -- Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases andnditions, today announced that its wholly owned subsidiary, Shaanxi Aoxing Pharmaceutical, entered into a Share]
[SHARE TRANSFERNTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS AND SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS INDEX CHAPATER I DEFINITION AND INTERPRETATION 4 ARTICLE 1 DEFINITION 4 CHAPATER II TRANSFERRED SHARES 5 ARTICLE 2 SHARE TRANSFER 5 ARTICLE 3 TRANSFER PRICE] [Form Non-competitionreementreement This Non-competitionreement (this Party A:Shaanxi Weinan Huaren Pharmaceuticals ampanyorporated under law, with its business license registered number [_] and its legaldress registered at No. 13, Weihua Road, Weinan City, Shaanxi Province; Party B:[_], a citizen with the ID number [_].] [BIOSTAR PHARMACEUTICALS SIGNSREEMENT TO ACQUIRE SHAANXI WEINAN HUAREN PHARMACEUTICALS, . XIANYANG, China, October 11, 2011 -- Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases andnditions, today announced that its wholly owned subsidiary, Shaanxi Aoxing Pharmaceutical, entered into a Share]
[SCHEDULE 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: ______________________________________ (2) Aggregate number of securities to which transaction applies: ______________________________________ (3) (4) Proposed maximum aggregate value of transaction: ______________________________________ (5) Total]
[SCHEDULE 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: ______________________________________ (2) Aggregate number of securities to which transaction applies: ______________________________________ (3) (4) Proposed maximum aggregate value of transaction: ______________________________________ (5) Total]
[SCHEDULE 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies:______________________________________ (2)gregate number of securities to which transaction applies:______________________________________ (3) (4) Proposed maximumgregate value of transaction: ______________________________________]
[SCHEDULE 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies:______________________________________ (2)gregate number of securities to which transaction applies:______________________________________ (3) (4) Proposed maximumgregate value of transaction: ______________________________________]
[FORM 10-Q (Mark One) x June 30, 2011 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
